Long-Term Quality of Life Assessment After Successful Endoscopic Vacuum Therapy of Defects in the Upper Gastrointestinal Tract Quality of Life After EVT.


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
02 2019
Historique:
received: 13 06 2018
accepted: 25 10 2018
pubmed: 16 11 2018
medline: 28 4 2020
entrez: 16 11 2018
Statut: ppublish

Résumé

Accumulating evidence indicates that anastomotic leakages and perforations of the upper gastrointestinal tract (uGIT) can be treated successfully with endoscopic vacuum therapy (EVT). So far, no data is available regarding the long-term quality of life (QoL) after successful EVT of defects in the uGIT. We present a prospective survey on long-term Qol of 52 patients treated by EVT for defects of the uGIT. Results are compared with 63 of 221 patients treated by esophagectomy without anastomotic insufficiency (w/o EVT) between 12/2011 and 12/2015. The Gastrointestinal Quality of Life-Index (GIQLI) score was determined by a 36-item questionnaire of 25 respondents with EVT and 50 respondents w/o EVT. The response rate was 78.95% (75/95) including 25 survey respondents who were treated with EVT for anastomotic insufficiency secondary to esophagectomy or gastrectomy (n = 19), iatrogenic esophageal perforation (n = 4), and Boerhaave syndrome (n = 2) and 50 respondents with complication-free esophagectomy w/o EVT. The median follow-up was 19 months for EVT patients and 21 months for patients w/o EVT. Except for "social function" (p = 0.009) in favor for patients w/o EVT, the median GIQLI score did not differ significantly between both study groups concerning the categories 'symptoms', 'emotions', 'physical functions', and 'medical treatment' resulting in a total median GIQLI score of 83 in EVT versus 96.5 in patients w/o EVT (p = 0.185). Spearman Rho analysis revealed that a high GIQLI score correlated with a low ASA score (p < 0.001), a benign pathology (p = 0.001), and a hospital stay less than 21 days (p < 0.001). EVT in the uGIT is well tolerated by the patients and accompanied by a satisfactory long-term QoL.

Sections du résumé

BACKGROUND
Accumulating evidence indicates that anastomotic leakages and perforations of the upper gastrointestinal tract (uGIT) can be treated successfully with endoscopic vacuum therapy (EVT). So far, no data is available regarding the long-term quality of life (QoL) after successful EVT of defects in the uGIT.
METHODS
We present a prospective survey on long-term Qol of 52 patients treated by EVT for defects of the uGIT. Results are compared with 63 of 221 patients treated by esophagectomy without anastomotic insufficiency (w/o EVT) between 12/2011 and 12/2015. The Gastrointestinal Quality of Life-Index (GIQLI) score was determined by a 36-item questionnaire of 25 respondents with EVT and 50 respondents w/o EVT.
RESULTS
The response rate was 78.95% (75/95) including 25 survey respondents who were treated with EVT for anastomotic insufficiency secondary to esophagectomy or gastrectomy (n = 19), iatrogenic esophageal perforation (n = 4), and Boerhaave syndrome (n = 2) and 50 respondents with complication-free esophagectomy w/o EVT. The median follow-up was 19 months for EVT patients and 21 months for patients w/o EVT. Except for "social function" (p = 0.009) in favor for patients w/o EVT, the median GIQLI score did not differ significantly between both study groups concerning the categories 'symptoms', 'emotions', 'physical functions', and 'medical treatment' resulting in a total median GIQLI score of 83 in EVT versus 96.5 in patients w/o EVT (p = 0.185). Spearman Rho analysis revealed that a high GIQLI score correlated with a low ASA score (p < 0.001), a benign pathology (p = 0.001), and a hospital stay less than 21 days (p < 0.001).
CONCLUSION
EVT in the uGIT is well tolerated by the patients and accompanied by a satisfactory long-term QoL.

Identifiants

pubmed: 30430432
doi: 10.1007/s11605-018-4038-9
pii: 10.1007/s11605-018-4038-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

280-287

Références

Hepatogastroenterology. 2001 Sep-Oct;48(41):1517-20
pubmed: 11677999
Ann Thorac Surg. 2010 Nov;90(5):1674-81
pubmed: 20971288
Br J Surg. 1995 Feb;82(2):216-22
pubmed: 7749697
Eur J Surg Oncol. 2000 Mar;26(2):168-71
pubmed: 10744938
Endoscopy. 2013 Jun;45(6):433-8
pubmed: 23733727
J Gastrointest Surg. 2015 Jul;19(7):1229-35
pubmed: 25967140
Surg Endosc. 2014 Mar;28(3):896-901
pubmed: 24149851
Endoscopy. 2014 Aug;46(8):693-711
pubmed: 25046348
Surg Endosc. 2017 Sep;31(9):3449-3458
pubmed: 28078463
J Gastrointest Surg. 2016 Feb;20(2):237-43
pubmed: 26643296
World J Surg. 2013 May;37(5):1051-9
pubmed: 23440483
Gastrointest Endosc. 2008 Apr;67(4):708-11
pubmed: 18374029
Surg Endosc. 2013 Jun;27(6):2040-5
pubmed: 23247743
Eur J Cardiothorac Surg. 2005 Jan;27(1):3-7
pubmed: 15621463
Surg Endosc. 2013 Oct;27(10):3883-90
pubmed: 23708716
Surg Endosc. 2017 Jun;31(6):2687-2696
pubmed: 27709328
Gastrointest Endosc. 2010 Feb;71(2):382-6
pubmed: 19879566
Surg Endosc. 2018 Apr;32(4):1906-1914
pubmed: 29218673
Ann Surg. 2014 May;259(5):852-60
pubmed: 24509201
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Endoscopy. 2010 Sep;42(9):693-8
pubmed: 20806153
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
J Gastrointest Surg. 2012 Nov;16(11):2145-50
pubmed: 22948839
Ann Thorac Cardiovasc Surg. 2004 Apr;10(2):71-5
pubmed: 15209546
Gastrointest Endosc. 2009 Mar;69(3 Pt 1):601-2; author reply 602
pubmed: 19231507
Aliment Pharmacol Ther. 2011 Jun;33(12):1292-301
pubmed: 21517921
Am J Surg. 2014 Oct;208(4):536-43
pubmed: 25151186
World J Gastroenterol. 2014 Jun 28;20(24):7767-76
pubmed: 24976714
Gastric Cancer. 2016 Jan;19(1):312-7
pubmed: 25627475
Ann Thorac Surg. 2014 Mar;97(3):1029-35
pubmed: 24444874

Auteurs

Sameer A Dhayat (SA)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Rosanna Schacht (R)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Rudolf Mennigen (R)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Daniel Palmes (D)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Thomas Vogel (T)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Thorsten Vowinkel (T)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Norbert Senninger (N)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany.

Mike Georg Laukoetter (MG)

Department of General and Visceral Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Bldg. W1, 48149, Muenster, Germany. laukoetter@uni-muenster.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH